Chi-Med Extends Oncology Commercial Reach To Realize China Potential
Sales Force Grows Nearly 10-Fold
Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.
You may also be interested in...
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
China’s latest volume-based purchase round is also the largest ever, covering more drugs and many of them are the widest-prescribed products. Novartis feels the pinch of price pressures but emphasizes a shift to new product launches.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.